ProMetic is a biopharmaceutical corporation with globally recognized expertise in bioseparation and uses its own affinity technology for the development of best in class plasma-derived therapeutics. ProMetic is also active in developing its own novel small molecule therapeutics products.
Headquartered in Laval, Canada, ProMetic has a global presence through its various sites in the UK and USA, providing both manufacturing and R&D capability. These strategic locations facilitate ProMetic’s growth globally and supports all business activity in American, European and Asian markets.
ProMetic is publicly traded on TSX (Symbol: PLI) and OTCQX (Symbol: PFSCF).
ProMetic has developed core competencies in strategic fields, including:
- Purification of biologics
- Drug development
- Elimination of pathogens
The business is now focused on developing its range of therapeutics from both its plasma-derived and small-molecule platform.